We’re proud to share that our LIVERFASt® performance study has been officially published, marking an important milestone in the non-invasive assessment of metabolic liver disease.

As highlighted by Dr. Naim Alkhouri, this publication helps establish LIVERFASt as a commercially available, clinically validated tool for the diagnosis and staging of MASLD / SLD, supported by data from three independent patient cohorts.

The study demonstrates:
• Strong diagnostic performance across fibrosis stages
• Consistent accuracy in metabolically complex populations
• Clear differentiation from legacy scores developed for other liver diseases

Equally important, this work lays the foundation for what comes next — evaluating LIVERFASt’s ability to monitor response to treatment, a critical need as therapeutic options for MASH continue to expand.

We are deeply grateful to the investigators, collaborators, and clinical partners whose dedication and patience made this work possible, and we look forward to continuing this journey together as we move from diagnosis to dynamic disease monitoring.

🔗 Read the publication here:
https://pubmed.ncbi.nlm.nih.gov/41453093/

#MASLD #SLD #MASH #LiverHealth #Diagnostics #NonInvasiveTesting #Fibronostics #ClinicalResearch